• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
my.AntidoteCME.com

my.AntidoteCME.com

Unique CE for You

  • Home
  • Course List
  • FAQ
  • About Us
  • Careers
  • Contact
  • Login
  • Create Account

Current Landscape and the New Emerging Therapies in EGFR-positive NSCLC

NSCLC: Current Landscape of First Line Treatement NSCLC: Current Landscape of First Line Treatment

Leading the way in NSCLC first-line treatment, Dr. Charu Aggarwal shares the latest insights. Get up to speed with this concise, informative video.

NSCLC: Initial Work-up and the Importance of NGS NSCLC: Initial Work-up and the Importance of NGS

Unlock the power of NGS in NSCLC work-up with Dr. Narjust Florez. In a short, insightful video, she discusses the importance of precise diagnostics.

NSCLC: Treatment after First Line NSCLC: Treatment after First Line

Transitioning from first-line treatment in NSCLC? Dr. Jack West provides expert insights in a concise video for community oncologists.

NSCLC: Current Treatment Options & the Role of ADCs NSCLC: Current Treatment Options & the Role of ADCs

Join the #OncologyBrothers and leading experts as they talk about the management of adv NSCLC mEGFR following World Lung. Earn CME/CE credit.

NSCLC: The Unmet Need from a Patient's Perspective 2L Treatment and Beyond NSCLC: The Unmet Need from a Patient's Perspective 2L Treatment and Beyond

Join Jill Feldman, a lung cancer advocate, as she teams up with the #OncologyBrothers to discuss the future after initial EGFR-positive NSCLC treatments fail.

Recent Advancements in NSCLC with Activating EGFR Mutations Recent Advancements in NSCLC with Activating EGFR Mutations

Tune in as Heather Wakelee, MD and the #OncologyBrothers explore promising second-line therapies for EGFR-mutated NSCLC. Learn how to integrate these breakthroughs into your clinical approach.

ADCs and Emerging EGFR Therapies for NSCLC ADCs and Emerging EGFR Therapies for NSCLC

Community Oncologists: Rami Manochakian M.D. shares groundbreaking data on ADCs for EGFR-positive NSCLC. Discover how new approaches to HER3-targeting can change your post-TKI treatment strategy.

Current Landscape and New Emerging Therapies in EGFR-Positive NSCLC Current Landscape and New Emerging Therapies in EGFR-Positive NSCLC

Dive into the latest advancements in EGFR-Positive NSCLC with Rami Manochakian, MD, Heather Wakelee MD & patient advocate Jill Friedman. Explore new therapies & real-world scenarios.

Videos in This Series

Contact

(888) 692-2631
5050 Quorum Dr, Ste 700-538
Dallas, Texas 75254

Copyright © 2015–2026 · Antidote Education Company · Privacy Policy